Comparative Pharmacology
Head-to-head clinical analysis: HICON versus SOLIFENACIN SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HICON versus SOLIFENACIN SUCCINATE.
HICON vs SOLIFENACIN SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Solifenacin is a competitive muscarinic receptor antagonist. It binds selectively to M3 muscarinic receptors, inhibiting acetylcholine action on smooth muscle of the urinary bladder, reducing detrusor overactivity and increasing bladder capacity.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
5 mg orally once daily, may increase to 10 mg once daily if tolerated.
None Documented
None Documented
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 45-68 hours (mean ~55 hours) in healthy adults, allowing once-daily dosing.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Primarily renal: ~69% as metabolites (including active metabolite 4R-hydroxy solifenacin) and ~7% as unchanged drug. Fecal excretion accounts for ~23% (mainly as metabolites).
Category C
Category A/B
Anticholinergic
Anticholinergic